Contemporary use of disease‐modifying drugs in the management of patients with early rheumatoid arthritis in Norway

References

• Machold K. P., Nell V., Stamm T., Aletaha D., Smolen J. S. Early rheumatoid arthritis. Curr Opin Rheumatol 2006; 18: 282–8
   PubMed Web of Science ®Google Scholar
• Machold K. P., Nell V. P., Stamm T. A., Smolen J. S. Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?. Arthritis Res Ther 2006; 8: 211
   PubMed Web of Science ®Google Scholar
• Jobanputra P., Wilson J., Douglas K., Burls A. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 206–10
   PubMed Web of Science ®Google Scholar
• Edwards C. J., Arden N. K., Fisher D., Saperia J. C., Reading I., Van Staa T. P., et al. The changing use of disease‐modifying anti‐rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44: 1394–8
   PubMedGoogle Scholar
• Sokka T., Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002; 29: 2521–4
   PubMed Web of Science ®Google Scholar
• Aletaha D., Eberl G., Nell V. P., Machold K. P., Smolen J. S. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 2002; 61: 630–4
   PubMed Web of Science ®Google Scholar
• Aletaha D., Smolen J. S. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41: 1367–74
   PubMed Web of Science ®Google Scholar
• Boers M., Verhoeven A. C., Markusse H. M., van de Laar M. A., Westhovens R., van Denderen J. C., et al. Randomised comparison of combined step‐down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309–18
   PubMed Web of Science ®Google Scholar
• Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999; 58: 220–5
   PubMed Web of Science ®Google Scholar
• Mottonen T., Hannonen P., Leirisalo‐Repo M., Nissila M., Kautiainen H., Korpela M., et al. Comparison of combination therapy with single‐drug therapy in early rheumatoid arthritis: a randomised trial. FIN‐RACo trial group. Lancet 1999; 353: 1568–73
   PubMed Web of Science ®Google Scholar
• Albers J. M., Paimela L., Kurki P., Eberhardt K. B., Emery P., van 't Hof M. A., et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 453–8
   PubMed Web of Science ®Google Scholar
• Scott D. L., Kingsley G. H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704–12
   PubMed Web of Science ®Google Scholar
• Kirwan J. R., Hallgren R., Mielants H., Wollheim F., Bjorck E., Persson T., et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 688–95
   PubMed Web of Science ®Google Scholar
• Kvien T. K., Heiberg, Lie E., Kaufmann C., Mikkelsen K., Nordvag B. Y., et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005; 23: S188–94
   PubMed Web of Science ®Google Scholar
• Bukhari M., Lunt M., Harrison B. J., Scott D. G., Symmons D. P., Silman A. J. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002; 46: 906–12
   PubMed Web of Science ®Google Scholar
• Combe B., Dougados M., Goupille P., Cantagrel A., Eliaou J. F., Sibilia J., et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44: 1736–43
   PubMed Web of Science ®Google Scholar
• Turesson C., O'Fallon W. M., Crowson C. S., Gabriel S. E., Matteson E. L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002; 29: 62–7
   PubMed Web of Science ®Google Scholar
• Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24
   PubMed Web of Science ®Google Scholar
• Sokka T., Pincus T. Ascendancy of weekly low‐dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. Rheumatology (Oxford) 2008; 47: 1543–7
   PubMed Web of Science ®Google Scholar
• Sokka T., Envalds M., Pincus T. Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs. Mod Rheumatol 2008; 18: 228–39
   PubMed Web of Science ®Google Scholar
• Esselens G., Westhovens R., Verschueren P. Effectiveness of an integrated outpatient care programme compared with present‐day standard care in early rheumatoid arthritis. Musculoskeletal Care. 2008, Epub ahead of print, DOI 10.1002/msc.136
   Google Scholar
• Papadopoulos N. G., Alamanos Y., Papadopoulos I. A., Tsifetaki N., Voulgari P. V., Drosos A. A. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long‐term observational study. J Rheumatol 2002; 29: 261–6
   PubMed Web of Science ®Google Scholar
• Riise T., Jacobsen B. K., Gran J. T. Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. Scand J Rheumatol 2001; 30: 199–202
   PubMed Web of Science ®Google Scholar
• Ludig A., Guillemin F., Chary‐Valckenaere I., Suurmeijer T. P., Moum T., van den Heuvel W. J. Drug consumption in the first years of rheumatoid arthritis in France, the Netherlands, and Norway. A longitudinal study in the early nineties. Scand J Rheumatol 2000; 29: 352–7
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., et al. Efficacy of low‐dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818–22
   PubMed Web of Science ®Google Scholar
• Williams H. J., Willkens R. F., Samuelson C. O., Jr, Alarcon G. S., Guttadauria M., Yarboro C., et al. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28: 721–30
   PubMed Web of Science ®Google Scholar
• Weinblatt M. E., Maier A. L., Fraser P. A., Coblyn J. S. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998; 25: 238–42
   PubMed Web of Science ®Google Scholar
• Hamilton R. A., Kremer J. M. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 86–90
   PubMedGoogle Scholar
• Van der Heijde D. M., van Riel P. L., van Leeuwen M. A., van 't Hof M. A., van Rijswijk M. H., van de Putte L. B. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow‐up study of 147 patients. Br J Rheumatol 1992; 31: 519–25
   PubMedGoogle Scholar
• Scott D. L. Prognostic factors in early rheumatoid arthritis. Rheumatology (Oxford) 2000; 39((Suppl 1))24–9
   PubMedGoogle Scholar
• Jansen L. M., van der Horst‐Bruinsma I. E., van Schaardenburg D., Bezemer P. D., Dijkmans B. A. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001; 60: 924–7
   PubMed Web of Science ®Google Scholar
• Graudal N., Tarp U., Jurik A. G., Galloe A. M., Garred P., Milman N., et al. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: longterm course and association to radiographic progression. J Rheumatol 2000; 27: 47–57
   PubMed Web of Science ®Google Scholar
• Shmerling R. H., Delbanco T. L. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991; 91: 528–34
   PubMed Web of Science ®Google Scholar
• Elliott J. R., O'Dell J. Rheumatoid arthritis. Rheumatology secrets, 2nd edn, S. G West. Hanley & Belfus, Philadelphia 2002; 123
   Google Scholar
• Eberhardt K. B., Fex E. Functional impairment and disability in early rheumatoid arthritis: development over 5 years. J Rheumatol 1995; 22: 1037–42
   PubMed Web of Science ®Google Scholar
• van der Heide A., Remme C. A., Hofman D. M., Jacobs J. W., Bijlsma J. W. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995; 38: 1466–74
   PubMed Web of Science ®Google Scholar
• van Everdingen A. A., Jacobs J. W., Siewertsz Van Reesema D. R., Bijlsma J. W. Low‐dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease‐modifying properties, and side effects: a randomized, double‐blind, placebo‐controlled clinical trial. Ann Intern Med 2002; 136: 1–12
   PubMed Web of Science ®Google Scholar
• Bas S., Genevay S., Meyer O., Gabay C. Anti‐cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 677–80
   PubMed Web of Science ®Google Scholar
• Nikolaisen C., Rekvig O. P., Nossent H. C. Diagnostic impact of contemporary biomarker assay for rheumatoid arthritis. Scand J Rheumatol 2007; 36: 97–100
   PubMed Web of Science ®Google Scholar